ELISA 분석기 시장 : 유형별, 모드별, 모달리티별, 용도별, 최종 용도별 - 세계 예측

Global ELISA Analyzers Market will witness over 4.2% CAGR from 2024 to 2032, driven by rising demand for personalized medicine based on a patient's unique genetic makeup, lifestyle, and specific health conditions. With an inclination towards patient-centric medical approaches, there is a growing need for diagnostic tools that offer precise and individualized results. Quoting an instance, in May 2024, Thermo Fisher Scientific launched a new range of advanced ELISA analyzers designed to enhance precision and throughput in personalized diagnostics. These tools aim to improve the detection of biomarkers critical for tailored treatment strategies.

Moreover, advancements in diagnostic technologies, which enhance the accuracy and efficiency of ELISA analyzers is favoring wider adoption. Rising prevalence of chronic diseases such as diabetes and cancer that necessitate regular monitoring and diagnostics, and increased government funding for healthcare infrastructure, which supports the adoption of advanced diagnostic tools in medical facilities will further bolster the market outlook.

The ELISA analyzers market is segmented based on type, mode, modality, application, end-use, and region.

The optical grating analyzers segment will record a remarkable CAGR through 2032, driven by the need for enhanced detection capabilities and improved accuracy. Optical grating technology offers superior sensitivity and resolution, enabling precise measurements of biological samples. As research and diagnostic applications become increasingly complex, there is a growing emphasis on obtaining highly accurate and reliable results. The incorporation of advanced analytical techniques for applications requiring detailed and nuanced data will fuel the demand for optical grating analyzers.

The semi-automated ELISA analyzers will procure a substantial market share by 2032, owing to the balance of operational efficiency and cost-effectiveness. Semi-automated systems streamline workflows by automating repetitive tasks while allowing for manual oversight, which enhances productivity without the high costs associated with fully automated systems. This combination appeals to laboratories seeking to improve throughput and accuracy while managing budget constraints. As laboratories and research facilities continue to focus on optimizing their processes and reducing manual errors, the adoption of semi-automated ELISA analyzers is expected to rise significantly.

North America ELISA analyzers market will exhibit a noteworthy CAGR during the forecast period, because of the strong emphasis on advanced healthcare and research. Significant investments in biomedical R&D, coupled with robust healthcare infrastructure, propel the need for sophisticated diagnostic tools. Additionally, the rising prevalence of chronic diseases and the increasing focus on personalized medicine boost the demand for precise diagnostic solutions. The high standard of medical care and supportive regulatory environment contribute to the growing adoption of ELISA analyzers across North America.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of chronic and infectious diseases
    • 3.2.1.2 Technological advancements in diagnostic testing
    • 3.2.1.3 Rising demand for portable and automated ELISA assays
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of devices
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Pricing analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Optical filter ELISA analyzers
• 5.3 Optical grating ELISA analyzers

Chapter 6 Market Estimates and Forecast, By Mode, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Automated ELISA analyzers
• 6.3 Semi-automated ELISA analyzers

Chapter 7 Market Estimates and Forecast, By Modality, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Bench-top
• 7.3 Stand-alone

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Immunology
• 8.3 Vaccine development
• 8.4 Drug monitoring & pharmaceutical industry
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Biotechnology companies
• 9.3 Pharmaceutical companies
• 9.4 Contract research organizations (CROs)
• 9.5 Diagnostic laboratories
• 9.6 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Agilent Technologies, Inc.
• 11.3 bioMerieux S.A.
• 11.4 Bio-Rad Laboratories, Inc.
• 11.5 Danaher Corporation
• 11.6 DiaSorin S.p.A.
• 11.7 DYNEX Technologies
• 11.8 Erba Mannheim
• 11.9 F. Hoffmann-La Roche Ltd
• 11.10 Merck KGaA
• 11.11 PerkinElmer, Inc.
• 11.12 Randox Laboratories Ltd.
• 11.13 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 11.14 Tecan Group Ltd.
• 11.15 Thermo Fisher Scientific Inc.